The results of immunotherapy in patients with recurrent and metastatic human papilloma virus positive head and neck squamous cell carcinoma
Human papilloma virus (HPV), primarily type 16 (less commonly type 18), is associated with oropharyngeal squamous cell carcinoma (OPSCC). According to literature data, between 25 and 70 % of all cases of this cancer are linked to HPV infection. In the USA and some countries of the European Union, HP...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2024-06-01
|
| Series: | Опухоли головы и шеи |
| Subjects: | |
| Online Access: | https://ogsh.abvpress.ru/jour/article/view/967 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849241589270970368 |
|---|---|
| author | A. V. Ignatova Yu. V. Alymov |
| author_facet | A. V. Ignatova Yu. V. Alymov |
| author_sort | A. V. Ignatova |
| collection | DOAJ |
| description | Human papilloma virus (HPV), primarily type 16 (less commonly type 18), is associated with oropharyngeal squamous cell carcinoma (OPSCC). According to literature data, between 25 and 70 % of all cases of this cancer are linked to HPV infection. In the USA and some countries of the European Union, HPV-associated OPSCC comprises 60-70 % of all cases of head and neck squamous cell carcinoma. HPV-associated OPSCC is characterized by more favorable prognosis and higher survival compared to HPV-negative OPSCC. These types of this pathology are differently characterized in the 8th edition Tumor, Nodus and Metastasis (TNM). Significant differences in survival and disease prognosis led to studies aimed at deintensification of standard OPSCC treatment to minimize adverse events without the loss of effectiveness. Despite more favorable clinical progression, in 15 % of patients with HPV-associated OPSCC even after standard therapy recurrences and/or regional/distant metastases are observed which lead to unfavorable prognosis. Modern treatment schemes for recurrent/metastatic head and neck squamous cell carcinoma include immunotherapy, results of which also depend on HPV-status of the tumor. While clinical trials studying effectiveness of immune drugs include patients with HPV-positive tumors, data on treatment outcomes are contradictory, and molecular mechanisms of HPV effect on the immune response are not fully understood.The article summarizes the data on the effect of positive HPV status on the effectiveness of immunotherapy in patients with progressing/metastatic head and neck squamous cell carcinoma. |
| format | Article |
| id | doaj-art-b7e92f4c4b71430c87cc9712ab7d5ece |
| institution | Kabale University |
| issn | 2222-1468 2411-4634 |
| language | Russian |
| publishDate | 2024-06-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Опухоли головы и шеи |
| spelling | doaj-art-b7e92f4c4b71430c87cc9712ab7d5ece2025-08-20T04:00:07ZrusABV-pressОпухоли головы и шеи2222-14682411-46342024-06-01141394810.17650/2222-1468-2024-14-1-39-48584The results of immunotherapy in patients with recurrent and metastatic human papilloma virus positive head and neck squamous cell carcinomaA. V. Ignatova0Yu. V. Alymov1N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia; Peoples' Friendship University of Russia (RUDN University)N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaHuman papilloma virus (HPV), primarily type 16 (less commonly type 18), is associated with oropharyngeal squamous cell carcinoma (OPSCC). According to literature data, between 25 and 70 % of all cases of this cancer are linked to HPV infection. In the USA and some countries of the European Union, HPV-associated OPSCC comprises 60-70 % of all cases of head and neck squamous cell carcinoma. HPV-associated OPSCC is characterized by more favorable prognosis and higher survival compared to HPV-negative OPSCC. These types of this pathology are differently characterized in the 8th edition Tumor, Nodus and Metastasis (TNM). Significant differences in survival and disease prognosis led to studies aimed at deintensification of standard OPSCC treatment to minimize adverse events without the loss of effectiveness. Despite more favorable clinical progression, in 15 % of patients with HPV-associated OPSCC even after standard therapy recurrences and/or regional/distant metastases are observed which lead to unfavorable prognosis. Modern treatment schemes for recurrent/metastatic head and neck squamous cell carcinoma include immunotherapy, results of which also depend on HPV-status of the tumor. While clinical trials studying effectiveness of immune drugs include patients with HPV-positive tumors, data on treatment outcomes are contradictory, and molecular mechanisms of HPV effect on the immune response are not fully understood.The article summarizes the data on the effect of positive HPV status on the effectiveness of immunotherapy in patients with progressing/metastatic head and neck squamous cell carcinoma.https://ogsh.abvpress.ru/jour/article/view/967human papillomavirushead and neck squamous cell carcinomaoropharyngeal squamous cell carcinomatargeted therapyimmunotherapyprogrammed death-ligand 1pembrolizumabnivolumab |
| spellingShingle | A. V. Ignatova Yu. V. Alymov The results of immunotherapy in patients with recurrent and metastatic human papilloma virus positive head and neck squamous cell carcinoma Опухоли головы и шеи human papillomavirus head and neck squamous cell carcinoma oropharyngeal squamous cell carcinoma targeted therapy immunotherapy programmed death-ligand 1 pembrolizumab nivolumab |
| title | The results of immunotherapy in patients with recurrent and metastatic human papilloma virus positive head and neck squamous cell carcinoma |
| title_full | The results of immunotherapy in patients with recurrent and metastatic human papilloma virus positive head and neck squamous cell carcinoma |
| title_fullStr | The results of immunotherapy in patients with recurrent and metastatic human papilloma virus positive head and neck squamous cell carcinoma |
| title_full_unstemmed | The results of immunotherapy in patients with recurrent and metastatic human papilloma virus positive head and neck squamous cell carcinoma |
| title_short | The results of immunotherapy in patients with recurrent and metastatic human papilloma virus positive head and neck squamous cell carcinoma |
| title_sort | results of immunotherapy in patients with recurrent and metastatic human papilloma virus positive head and neck squamous cell carcinoma |
| topic | human papillomavirus head and neck squamous cell carcinoma oropharyngeal squamous cell carcinoma targeted therapy immunotherapy programmed death-ligand 1 pembrolizumab nivolumab |
| url | https://ogsh.abvpress.ru/jour/article/view/967 |
| work_keys_str_mv | AT avignatova theresultsofimmunotherapyinpatientswithrecurrentandmetastatichumanpapillomaviruspositiveheadandnecksquamouscellcarcinoma AT yuvalymov theresultsofimmunotherapyinpatientswithrecurrentandmetastatichumanpapillomaviruspositiveheadandnecksquamouscellcarcinoma AT avignatova resultsofimmunotherapyinpatientswithrecurrentandmetastatichumanpapillomaviruspositiveheadandnecksquamouscellcarcinoma AT yuvalymov resultsofimmunotherapyinpatientswithrecurrentandmetastatichumanpapillomaviruspositiveheadandnecksquamouscellcarcinoma |